Evidence map›Paper›PMID 25982306›Full record

ArticleThe Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases

Microarray-based genotyping and detection of drug-resistant HBV mutations from 620 Chinese patients with chronic HBV infection.

Wenhao Hua, Guanbin Zhang, Shujun Guo, Weijie Li, Lanhua Sun, Guangxin Xiang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Association of PRKAA1 gene polymorphisms with chronic hepatitis B virus infection in Chinese Han population.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wenhao HuaDepartment of Clinical Laboratory, Beijing Ditan Hospital, Capital Medical University, Beijing, China. Electronic address: dtjykhua@126.com.
Guanbin ZhangNational Engineering Research Center for Beijing Biochip Technology, Beijing, China.
Shujun GuoDepartment of Infectious Disease, Pingdingshan General Hospital Medical Group, Pingdingshan City, Henan Province, China.
Weijie LiDepartment of Clinical Laboratory, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Lanhua SunNational Engineering Research Center for Beijing Biochip Technology, Beijing, China.
Guangxin XiangNational Engineering Research Center for Beijing Biochip Technology, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundResearch has shown that hepatitis B virus (HBV) genotypes are closely linked to the clinical manifestations, treatment, and prognosis of the disease.

objectiveTo study the association between genotype and drug-resistant HBV mutations in 620 Chinese patients with chronic HBV infection.

methodsHBV DNA levels were determined using real-time quantitative PCR in plasma samples. Microarrays were performed for the simultaneous detection of HBV genotypes (HBV/B, C, and D) and drug-resistance-related hotspot mutations. A portion of the samples analyzed using microarrays was selected randomly and the data were confirmed using direct DNA sequencing.

resultsMost samples were genotype C (471/620; 76.0%), followed by genotype B (149/620; 24.0%). Among the 620 patient samples, 17 (2.7%) had nucleotide analogs (NA) resistance-related mutations. Of these, nine and eight patients carried lamivudine (LAM)-/telbivudine (LdT)-resistance mutations (rtL180M, rtM204I/V) and adefovir (ADV)-resistance mutations (rtA181T/V, rtN236T), respectively. No patients had both lamivudine (LAM)- and either adefovir (ADV) or entecavir (ETV) resistance mutations. Additionally, out of the 620 patient samples, 64.0% (397/620) were also detected with the precore stop-codon mutation (G1896A) by microarray assay.

conclusionThe results of the current study revealed that the prevalence of nucleotide analogs (NA)-resistance in Chinese hospitalized HBV-positive patients was so low that intensive nucleotide analogs (NA)-resistance testing before nucleotide analog (NA) treatment might not be required. In addition, the present study suggests that chronic HBV patients with genotype C were infected with fitter viruses and had an increased prevalence of nucleotide analogs (NA)-resistance mutations compared to genotype B virus.

Indexed as

MutationAdenineAdultAntiviral AgentsAsian PeopleDNA, ViralDrug Resistance, ViralFemaleGenotypeGuanineHepatitis B, ChronicHepatitis B virusHumansLamivudineMaleMicroarray AnalysisadefovirAdenineAntiviral AgentsDNA, ViralentecavirGuanineLamivudineOrganophosphonatesTelbivudineThymidineChronic HBVDrug-resistance mutationsGenotypingMicroarray

Identifiers

PMID25982306
PMCPMC9425391

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.